Fox Run Management’s TG Therapeutics TGTX Stock Holding History

Fox Run Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-9,832	Closed	-$354K	–	1231
2025 Q2	$354K	Sell	9,832 -9,171	-48%	-$341K	0.06%	596
2025 Q1	$749K	Buy	+19,003	New	+$639K	0.12%	307
2024 Q2	–	Sell	-50,724	Closed	-$772K	–	1077
2024 Q1	$772K	Buy	50,724 +23,061	+83%	+$367K	0.17%	224
2023 Q4	$472K	Buy	27,663 +11,884	+75%	+$138K	0.12%	329
2023 Q3	$132K	Buy	+15,779	New	+$220K	0.04%	607
2023 Q2	–	Sell	-25,736	Closed	-$387K	–	956
2023 Q1	$387K	Buy	+25,736	New	+$391K	0.13%	316
2018 Q2	–	Sell	-16,738	Closed	-$238K	–	911
2018 Q1	$238K	Buy	+16,738	New	+$214K	0.06%	575
2017 Q3	–	Sell	-15,500	Closed	-$156K	–	860
2017 Q2	$156K	Buy	+15,500	New	+$173K	0.05%	570
2017 Q1	–	Sell	-18,600	Closed	-$86K	–	745
2016 Q4	$86K	Buy	+18,600	New	+$109K	0.05%	473

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fox Run Management's TGTX Position: Q3 2025 in Review

Fox Run Management sold out of TG Therapeutics (TGTX) in Q3 2025, closing a stake of 9,832 shares — an estimated $354K sold.

Fox Run Management first reported a position in TGTX in Q4 2016 and held it in 9 quarters. The position peaked at $772K in Q1 2024. 354 funds tracked by Wall St. Rank hold TGTX as of Q3 2025.

Fox Run Management reported no remaining TG Therapeutics position as of Q3 2025 after selling out during the quarter.
Fox Run Management sold 9,832 TG Therapeutics shares in Q3 2025, an estimated $354K.
Fox Run Management first reported a position in TG Therapeutics in Q4 2016 and held it in 9 quarters.
Fox Run Management's TG Therapeutics position peaked at $772K in Q1 2024.
354 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2025.

Based on Fox Run Management's 13F filing for Q3 2025, filed 12 Nov 2025.